 |
|
Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
September 15, 2008Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH). The study was published online ahead of print September 15, 2008, in the American Journal of Psychiatry.
"Schizophrenia and schizophrenia-related disorders are rare in childhood. But when they do occur, those afflicted generally have more severe symptoms and a worse prognosis than those who develop the disorder in adulthood," said NIMH Director Thomas R. Insel, M.D. "The newer atypical antipsychotics are often used to treat these children, but until now, it has been unclear how effective and safe they really are in children. The side effects of the newer medications should be factored into making treatment decisions."
The six-year, multisite Treatment of Early Onset Schizophrenia Study (TEOSS) included 116 youth between 8 and 19 years old, diagnosed with early onset schizophrenia spectrum disorder (EOSS). The TEOSS team randomly assigned the children to eight weeks of either olanzapine (Zyprexa) or risperidone (Risperdal)-both new generation atypical antipsychotics-or to the older conventional antipsychotic molindone (Moban) plus benztropine, a medication often used to reduce side effects like uncontrolled shaking or tremor that can be associated with molindone. The children were monitored throughout the study by an NIMH oversight board to ensure their safety.
Response rates after eight weeks of treatment were comparable among the three medications-50 percent of the children taking molindone improved, 46 percent taking risperidone improved, and 34 percent taking olanzapine improved. Children taking olanzapine or risperidone improved within the first two weeks, while the children on molindone improved within three weeks.
The treatment groups did differ in side effects. The children taking olanzapine gained about 13 pounds (6 kilograms) during the trial on average, while children taking risperidone gained about 8 pounds (3.6 kilograms), and those taking molindone did not gain weight. The olanzapine group also showed increases in cholesterol levels and other metabolic disruptions that may have become dangerous. The outcome prompted the safety review board to end the olanzapine arm of the study in 2006.
"Atypical antipsychotics are commonly used to treat kids with EOSS, but these results question the wisdom of that approach," said lead author Linmarie Sikich, M.D., of the University of North Carolina at Chapel Hill. "They also remind us that we need to develop safer, more effective medications to treat these children, given the limited effectiveness of both the atypical and the conventional medications."
Study coauthor Jeffery Lieberman, M.D., of Columbia University Medical Center, noted that TEOSS is the first documented evidence of how newer antipsychotics compare to older ones when treating children and adolescents with schizophrenia. "Doctors need to educate families about the potentially serious side effects these drugs can have so that strategies can be put into place to address them," he reiterated. The TEOSS results are similar to those found in the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), for which Lieberman was the principal investigator. CATIE found that the newer antipsychotics were no more effective than an older antipsychotic in treating adults with schizophrenia.
NIH/National Institute of Mental Health
Response rates after eight weeks of treatment were comparable among the three medications-50 percent of the children taking molindone improved, 46 percent taking risperidone improved, and 34 percent taking olanzapine improved. Children taking olanzapine or risperidone improved within the first two weeks, while the children on molindone improved within three weeks.
The treatment groups did differ in side effects. The children taking olanzapine gained about 13 pounds (6 kilograms) during the trial on average, while children taking risperidone gained about 8 pounds (3.6 kilograms), and those taking molindone did not gain weight. The olanzapine group also showed increases in cholesterol levels and other metabolic disruptions that may have become dangerous. The outcome prompted the safety review board to end the olanzapine arm of the study in 2006.
"Atypical antipsychotics are commonly used to treat kids with EOSS, but these results question the wisdom of that approach," said lead author Linmarie Sikich, M.D., of the University of North Carolina at Chapel Hill. "They also remind us that we need to develop safer, more effective medications to treat these children, given the limited effectiveness of both the atypical and the conventional medications."
Study coauthor Jeffery Lieberman, M.D., of Columbia University Medical Center, noted that TEOSS is the first documented evidence of how newer antipsychotics compare to older ones when treating children and adolescents with schizophrenia. "Doctors need to educate families about the potentially serious side effects these drugs can have so that strategies can be put into place to address them," he reiterated. The TEOSS results are similar to those found in the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), for which Lieberman was the principal investigator. CATIE found that the newer antipsychotics were no more effective than an older antipsychotic in treating adults with schizophrenia.
NIH/National Institute of Mental Health
Schizophrenia Current Events and Schizophrenia News RSSClaudin 11 stops the leaks in neuronal myelin sheaths
Devaux and Gow demonstrate how a tight junction protein called claudin 11 makes the neuronal myelin sheath a snug fit.
Lower childhood IQ associated with higher risk of adult mental disorders
Researchers have hypothesized that people with lower IQs may have a higher risk of adult mental disorders, but few studies have looked at the relationship between low childhood IQ and psychiatric disorders later in life.
Prognosis after attempted suicide impaired by psychiatric disorder
People who have attempted suicide at some point in their lives are more likely to actually succeed in committing suicide at a later date.
Routine Testing After Aneurysm Coiling Carries Low Risk
A very low risk of complication is associated with a routine test that determines whether a brain aneurysm treated with endovascular coiling has started to recur, a study led by the University of Cincinnati Neuroscience Institute has shown.
Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find
Researchers at UT Southwestern Medical Center have uncovered new insights into the "Dr. Jekyll and Mr. Hyde" nature of a protein that stimulates stem-cell maturation in the brain but, paradoxically, can also lead to nerve-cell damage.
Pivotal Emory study focuses on teens at risk for psychosis
Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder.
Interaction between gene variants may alter brain function in schizophrenia
A collaborative study led by investigators from Massachusetts General Hospital (MGH) is giving what may be the first look at how interactions between genes underlie a key symptom of schizophrenia, impaired working memory.
Mental health linked to stillbirth and newborn deaths
Women with a history of serious mental illness are much more likely to have babies that are stillborn or die within the first month of life, new research reveals.
Pitt research identifies new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug.
Research shows raised incidence of psychoses among migrant groups
Researchers examining the occurrence of psychoses among migrant groups have shown a raised incidence for all black and ethnic minority subgroups compared with white British counterparts, and reveal that the risk of psychoses for first and second generations varies by ethnicity.
More Schizophrenia Current Events and Schizophrenia News Articles
 | Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (4th Edition) by E. Fuller Torrey Since its first publication in 1983, Surviving Schizophrenia has become the standard reference book on the disease and has helped thousands of patients, their families and mental health professionals. In clear language, this much–praised and important book describes the nature, causes, symptoms, treatment and course of schizophrenia and also explores living with it from both the patient and the... |
 | Schizophrenia For Dummies (For Dummies (Health & Fitness)) by Jerome Levine, Irene S. Levine Practical tools for leading a happy, productive life Schizophrenia is a chronic, severe, and disabling mental disorder that afflicts one percent of the population, an estimated 2.5 million people in America alone. The firsthand advice in this reassuring guide will empower the families and caregivers of schizophrenia patients to take charge, offering expert advice on identifying the warning... |
 | The Complete Family Guide to Schizophrenia: Helping Your Loved One Get the Most Out of Life by Kim T. Mueser, Susan Gingerich Do people with schizophrenia ever get better? With the vast majority of those with the disorder dependent on their families for care, close relatives often grapple with that question. The Complete Family Guide to Schizophrenia inspires hope. Authors Kim T. Mueser, PhD, and Susan Gingerich, MSW, walk readers through a range of treatment and support options that can lead to a better life for the... |
 | Schizophrenia: Cognitive Theory, Research, and Therapy by Aaron T. Beck, Neil A. Rector, Neal Stolar, Paul Grant From Aaron T. Beck and colleagues, this is the definitive work on the cognitive model of schizophrenia and its treatment. The volume integrates cognitive-behavioral and biological knowledge into a state-of-the-science conceptual framework. It comprehensively examines the origins, development, and maintenance of key symptom areas: delusions, hallucinations, negative symptoms, and formal thought... |
 | Getting Your Life Back Together When You Have Schizophrenia by Roberta Temes |
 | Me, Myself, and Them: A Firsthand Account of One Young Person's Experience with Schizophrenia (Adolescent Mental Health Initiative) by Kurt Snyder, Raquel E. Gur, Linda Wasmer Andrews During his second semester at college, Kurt Snyder became convinced that he was about to discover a fabulously important mathematical principle, spending hours lost in daydreams about numbers and symbols. In time, his thoughts took a darker turn, and he became preoccupied with the idea that cars were following him, or that strangers wanted to harm him. Kurt's mind had been hijacked by... |
 | Cognitive Therapy of Schizophrenia (Guides to Individualized Evidence-Based Treatment) by David G. Kingdon, Douglas Turkington Drawing on the authors' decades of influential work in the field, this highly practical volume presents an evidence-based cognitive therapy approach for clients with schizophrenia. Guidelines are provided for collaborative assessment and case formulation that enable the clinician to build a strong therapeutic relationship, establish reasonable goals, and tailor treatment to each client's needs.... |
 | Recovered, Not Cured: A Journey Through Schizophrenia by Richard McLean This very personal exploration of schizophrenia explores each stage, from the early signs and reactions from friends and family to seeking help and the challenges of recovery. McLean bravely shares his paranoid delusions and offers both a verbal and a visual experience by including digital artwork he created to help objectify and control his impulses and fears. As McLean relates his experiences... |
 | Stalking Irish Madness: Searching for the Roots of My Family's Schizophrenia by Patrick Tracey In this powerful, sometimes harrowing, deeply felt story, Patrick Tracey journeys to Ireland to track the origin and solve the mystery of his Irish-American family's multigenerational struggle with schizophrenia.For most Irish Americans, a trip to Ireland is often an occasion to revisit their family's roots. But for Patrick Tracey, the lure of his ancestral home is a much more powerful need: part... |
 | Diagnosis: Schizophrenia by Rachel Miller, Susan Mason The disease is not fatal but few diagnoses have the capacity to instill as much fear in the hearts of patients and families. Here is a profoundly reassuring book that shows there can be life after a diagnosis of schizophrenia. The book includes thirty-five first-person accounts, along with chapters by professionals on a wide range of issues from hospitalization to rehabilitation. Jargon-free... |
| © 2008 BrightSurf.com |